Business, energy, technology, markets and global industry news from Business News Today

United Therapeutics Corporation

PharmaDeviceNews United Therapeutics Corporation
Editorial infographic showing United Therapeutics’ FDA clearance for the SUMMIT PH-COPD trial, featuring a treprostinil inhaler, illustrated lungs, clinical trial imagery, and key safety considerations.
Pharma & Biotech

United Therapeutics advances SUMMIT study targeting pulmonary hypertension in COPD

United Therapeutics secures FDA clearance for its SUMMIT PH-COPD trial. Can a new treprostinil inhaler overcome earlier safety concerns?

Read More
Representative image: FDA approval of United Therapeutics Corporation’s LungFX device could expand centralized ex vivo lung perfusion for donor lung evaluation and transplantation.
Medical Devices & Diagnostics

United Therapeutics wins FDA approval for LungFX, but pivotal survival data may shape uptake

The LungFX approval gives United Therapeutics control of a centralized donor lung evaluation platform, although clinical warnings, logistics and economics will influence adoption.

Read More
Representative image: A surgical team prepares a preserved donor heart in a high-tech transplant setting, reflecting the clinical and regulatory stakes behind United Therapeutics Corporation’s FDA-cleared UHeart xenotransplantation trial for end-stage heart failure.
Pharma & Biotech

Why United Therapeutics’ FDA-cleared UHeart trial could redefine xenotransplantation risk

Find out how United Therapeutics’ FDA-cleared UHeart trial could reshape xenotransplantation for end-stage heart failure patients.

Read More
Pharma & Biotech

Can Tyvaso change the treatment pathway for idiopathic pulmonary fibrosis after TETON-1?

IPF has few durable treatment options. Tyvaso’s TETON data may test whether inhaled therapy can reset the regulatory and commercial playbook.

Read More
Representative image: A surgical team prepares a preserved donor heart in a high-tech transplant setting, reflecting the clinical and regulatory stakes behind United Therapeutics Corporation’s FDA-cleared UHeart xenotransplantation trial for end-stage heart failure.
Pharma & Biotech

Can United Therapeutics turn pig-heart xenotransplantation into a regulated clinical pathway?

A pig-heart trial is no longer just a scientific leap. United Therapeutics now faces the harder test of safety, scale, and regulation.

Read More
Pharma & Biotech

How United Therapeutics is betting on scaffold-based liver support in high-mortality ALF

United Therapeutics’ miroliverELAP showed positive phase 1 safety results in acute liver failure. Find out what this could mean for future liver support strategies.

Read More